The European Medicines Agency's Scientific Advisory Group ...
Eisai announced the Scientific Advisory Group (SAG) will discuss lecanemab's Marketing Authorisation Application (MAA) in the EU, with a decision expected in Q2 2024. Lecanemab, developed with BioArctic, is a treatment for Alzheimer's, approved in the US, Japan, and China. BioArctic plans to commercialize lecanemab in the Nordic region with Eisai.
Reference News
The European Medicines Agency's Scientific Advisory Group ...
Eisai announced the Scientific Advisory Group (SAG) will discuss lecanemab's Marketing Authorisation Application (MAA) in the EU, with a decision expected in Q2 2024. Lecanemab, developed with BioArctic, is a treatment for Alzheimer's, approved in the US, Japan, and China. BioArctic plans to commercialize lecanemab in the Nordic region with Eisai.